Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Economic Data Deluge

by Zacks Equity Research

Economic Data Deluge

Mark Vickery headshot

New Stimulus, Moderna & Durable Goods Kick Off Monday

by Mark Vickery

We have $1 trillion in stimulus expected from the congressional GOP today and a phase 3 trial beginning for Moderna's (MRNA) COVID-19 vaccine candidate.

Sanghamitra Saha headshot

3 Top Sector ETFs to Start Q3 With More Room for Growth

by Sanghamitra Saha

We entered the third quarter some weeks ago with no abatement (rather surges) on the virus front and several U.S. states reversing the course of economic reopening.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain on Coronavirus Vaccine Progress

by Sweta Jaiswal, FRM

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

Zacks Equity Research

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax

Kaibalya Pravo Dey headshot

EU Stimulus, Vaccine Hopes Aid Oil Price, Upstream Stocks Rise

by Kaibalya Pravo Dey

Significant gains in crude prices are likely to provide a profit-boosting opportunity to exploration and production companies.

Zacks Equity Research

3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data

by Zacks Equity Research

Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.

David Borun headshot

Quiet Week Could be the Calm Before the Storm

by David Borun

A busy week of earnings reports and Congressional stimulus talks has t

Sweta Killa headshot

Top and Flop ETFs to Start Third Quarter

by Sweta Killa

We have highlighted ETFs from the best and worst zones to start the third quarter.

Zacks Equity Research

Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress

by Zacks Equity Research

Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.